id,source,text,arguments
0,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son can develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
1,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son can have developed acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
2,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son develops acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
3,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son has the ability to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
4,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son has the risk of developing acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
5,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is able to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
6,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is believed to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
7,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is developing acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
8,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is found to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
9,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is observed to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
10,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is predicted to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
11,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son is shown to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
12,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son may develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
13,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son may have developed acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
14,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son will develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
15,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) is identified in an asymptomatic female carrier whose son will have developed acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
16,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son could develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
17,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son had the ability to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
18,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son had the risk of developing acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
19,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son has been developing acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
20,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son has developed acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
21,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son might develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
22,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was believed to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
23,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was developing acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
24,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was found to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
25,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was observed to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
26,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was predicted to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
27,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son was shown to develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
28,EGRAM,A C-to-T transition in codon 214 creating a new RsaI recognition site in exon 6 and substituting tyrosine for histidine (H214Y) was identified in an asymptomatic female carrier whose son would develop acute neonatal onset of OTC deficiency.,{'0': 'whose son'}
29,EGRAM,"Although Pin1 -/- mice are able to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
30,EGRAM,"Although Pin1 -/- mice are believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
31,EGRAM,"Although Pin1 -/- mice are believed to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
32,EGRAM,"Although Pin1 -/- mice are found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
33,EGRAM,"Although Pin1 -/- mice are found to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
34,EGRAM,"Although Pin1 -/- mice are predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
35,EGRAM,"Although Pin1 -/- mice are predicted to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
36,EGRAM,"Although Pin1 -/- mice are previously able to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
37,EGRAM,"Although Pin1 -/- mice are previously believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
38,EGRAM,"Although Pin1 -/- mice are previously believed to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
39,EGRAM,"Although Pin1 -/- mice are previously found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
40,EGRAM,"Although Pin1 -/- mice are previously found to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
41,EGRAM,"Although Pin1 -/- mice are previously predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
42,EGRAM,"Although Pin1 -/- mice are previously predicted to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
43,EGRAM,"Although Pin1 -/- mice are previously shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
44,EGRAM,"Although Pin1 -/- mice are previously shown to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
45,EGRAM,"Although Pin1 -/- mice are shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
46,EGRAM,"Although Pin1 -/- mice are shown to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
47,EGRAM,"Although Pin1 -/- mice can develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
48,EGRAM,"Although Pin1 -/- mice can have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
49,EGRAM,"Although Pin1 -/- mice can have previously developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
50,EGRAM,"Although Pin1 -/- mice can previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
51,EGRAM,"Although Pin1 -/- mice could develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
52,EGRAM,"Although Pin1 -/- mice could previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
53,EGRAM,"Although Pin1 -/- mice have been believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
54,EGRAM,"Although Pin1 -/- mice have been believed to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
55,EGRAM,"Although Pin1 -/- mice have been found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
56,EGRAM,"Although Pin1 -/- mice have been found to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
57,EGRAM,"Although Pin1 -/- mice have been predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
58,EGRAM,"Although Pin1 -/- mice have been predicted to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
59,EGRAM,"Although Pin1 -/- mice have been shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
60,EGRAM,"Although Pin1 -/- mice have been shown to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
61,EGRAM,"Although Pin1 -/- mice have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
62,EGRAM,"Although Pin1 -/- mice have previously been believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
63,EGRAM,"Although Pin1 -/- mice have previously been believed to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
64,EGRAM,"Although Pin1 -/- mice have previously been found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
65,EGRAM,"Although Pin1 -/- mice have previously been found to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
66,EGRAM,"Although Pin1 -/- mice have previously been predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
67,EGRAM,"Although Pin1 -/- mice have previously been predicted to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
68,EGRAM,"Although Pin1 -/- mice have previously been shown to have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
69,EGRAM,"Although Pin1 -/- mice have previously developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
70,EGRAM,"Although Pin1 -/- mice may develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
71,EGRAM,"Although Pin1 -/- mice may have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
72,EGRAM,"Although Pin1 -/- mice may have previously developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
73,EGRAM,"Although Pin1 -/- mice may previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
74,EGRAM,"Although Pin1 -/- mice might develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
75,EGRAM,"Although Pin1 -/- mice might previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
76,EGRAM,"Although Pin1 -/- mice were able to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
77,EGRAM,"Although Pin1 -/- mice were believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
78,EGRAM,"Although Pin1 -/- mice were found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
79,EGRAM,"Although Pin1 -/- mice were predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
80,EGRAM,"Although Pin1 -/- mice were previously able to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
81,EGRAM,"Although Pin1 -/- mice were previously believed to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
82,EGRAM,"Although Pin1 -/- mice were previously found to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
83,EGRAM,"Although Pin1 -/- mice were previously predicted to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
84,EGRAM,"Although Pin1 -/- mice were previously shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
85,EGRAM,"Although Pin1 -/- mice were shown to develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
86,EGRAM,"Although Pin1 -/- mice will develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
87,EGRAM,"Although Pin1 -/- mice will have developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
88,EGRAM,"Although Pin1 -/- mice will have previously developed normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
89,EGRAM,"Although Pin1 -/- mice will previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
90,EGRAM,"Although Pin1 -/- mice would develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
91,EGRAM,"Although Pin1 -/- mice would previously develop normally (Fujimori et al., 1999), we have uncovered that they display a range of cell proliferative abnomalities, including decreased body size, retinal degenration and neurological abnormalities.","{'0': 'mice', 'M-MAN': 'normally'}"
92,EGRAM,"It has been planted from September up to the end of October, and has been observed to develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
93,EGRAM,"It has been planted from September up to the end of October, and has developed into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
94,EGRAM,"It is planted from September up to the end of October, and can develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
95,EGRAM,"It is planted from September up to the end of October, and can obviously develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
96,EGRAM,"It is planted from September up to the end of October, and develops into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
97,EGRAM,"It is planted from September up to the end of October, and has the ability to develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
98,EGRAM,"It is planted from September up to the end of October, and is able to develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
99,EGRAM,"It is planted from September up to the end of October, and is believed to develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
100,EGRAM,"It is planted from September up to the end of October, and is predicted to develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
101,EGRAM,"It is planted from September up to the end of October, and may develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
102,EGRAM,"It is planted from September up to the end of October, and may obviously develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
103,EGRAM,"It is planted from September up to the end of October, and will be shown to develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
104,EGRAM,"It will be planted from September up to the end of October, and will develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
105,EGRAM,"It will be planted from September up to the end of October, and will obviously develop into the rosette stage and keeps on growing until the end of November.","{'0': 'It', '2': 'the rosette stage'}"
106,EGRAM,Spinach sown in October being able to develop into the rosette stage grows through the end of November.,{'2': 'the rosette stage'}
107,EGRAM,Spinach sown in October can develop into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
108,EGRAM,Spinach sown in October can have developed into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
109,EGRAM,Spinach sown in October could develop into the rosette stage and grew through the end of November.,{'2': 'the rosette stage'}
110,EGRAM,Spinach sown in October developed into the rosette stage and grew through the end of November.,{'2': 'the rosette stage'}
111,EGRAM,Spinach sown in October developing into the rosette stage grows through the end of November.,{'2': 'the rosette stage'}
112,EGRAM,Spinach sown in October had the ability to develop into the rosette stage and grew through the end of November.,{'2': 'the rosette stage'}
113,EGRAM,Spinach sown in October has been developing into the rosette stage and can grow through the end of November.,{'2': 'the rosette stage'}
114,EGRAM,Spinach sown in October has developed into the rosette stage and grown through the end of November.,{'2': 'the rosette stage'}
115,EGRAM,Spinach sown in October has the ability to develop into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
116,EGRAM,Spinach sown in October is able to develop into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
117,EGRAM,Spinach sown in October is believed to develop into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
118,EGRAM,Spinach sown in October is developing into the rosette stage and will grow through the end of November.,{'2': 'the rosette stage'}
119,EGRAM,Spinach sown in October is found to develop into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
120,EGRAM,Spinach sown in October is predicted to develop into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
121,EGRAM,Spinach sown in October is shown to develop into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
122,EGRAM,Spinach sown in October may develop into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
123,EGRAM,Spinach sown in October may have developed into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
124,EGRAM,Spinach sown in October might develop into the rosette stage and grew through the end of November.,{'2': 'the rosette stage'}
125,EGRAM,Spinach sown in October that can develop into the rosette stage grows through the end of November.,{'2': 'the rosette stage'}
126,EGRAM,Spinach sown in October that develops into the rosette stage grows through the end of November.,{'2': 'the rosette stage'}
127,EGRAM,Spinach sown in October that is able to develop into the rosette stage grows through the end of November.,{'2': 'the rosette stage'}
128,EGRAM,Spinach sown in October was able to develop into the rosette stage and grew through the end of November.,{'2': 'the rosette stage'}
129,EGRAM,Spinach sown in October was believed to develop into the rosette stage and grew through the end of November.,{'2': 'the rosette stage'}
130,EGRAM,Spinach sown in October develops into the rosette stage and grows through the end of November.,"{'0': 'Spinach sown in October', '2': 'the rosette stage'}"
131,EGRAM,"Spinach sown in October, which develops into the rosette stage, grows through the end of November.","{'0': 'Spinach sown in October', '2': 'the rosette stage'}"
132,EGRAM,"Spinach sown in October, which grows through the end of November, develops into the rosette stage.","{'0': 'Spinach sown in October', '2': 'the rosette stage'}"
133,EGRAM,Spinach sown in October was found to develop into the rosette stage and grew through the end of November.,{'2': 'the rosette stage'}
134,EGRAM,Spinach sown in October was predicted to develop into the rosette stage and grew through the end of November.,{'2': 'the rosette stage'}
135,EGRAM,Spinach sown in October was shown to develop into the rosette stage and grew through the end of November.,{'2': 'the rosette stage'}
136,EGRAM,Spinach sown in October which can develop into the rosette stage grows through the end of November.,{'2': 'the rosette stage'}
137,EGRAM,Spinach sown in October which develops into the rosette stage grows through the end of November.,{'2': 'the rosette stage'}
138,EGRAM,Spinach sown in October which is able to develop into the rosette stage grows through the end of November.,{'2': 'the rosette stage'}
139,EGRAM,Spinach sown in October will develop into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
140,EGRAM,Spinach sown in October will have developed into the rosette stage and grow through the end of November.,{'2': 'the rosette stage'}
141,EGRAM,Spinach sown in October would develop into the rosette stage and grew through the end of November.,{'2': 'the rosette stage'}
142,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we are able to develop a novel screening system.",{'0': 'we'}
143,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we are ready to develop a novel screening system.",{'0': 'we'}
144,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we can develop a novel screening system.",{'0': 'we'}
145,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we can have developed a novel screening system.",{'0': 'we'}
146,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we choose to develop a novel screening system.",{'0': 'we'}
147,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we chose to develop a novel screening system.",{'0': 'we'}
148,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we could develop a novel screening system.",{'0': 'we'}
149,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we decide to develop a novel screening system.",{'0': 'we'}
150,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we decided to develop a novel screening system.",{'0': 'we'}
151,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we develop a novel screening system.",{'0': 'we'}
152,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we developed a novel screening system.",{'0': 'we'}
153,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we had the ability to develop a novel screening system.",{'0': 'we'}
154,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have been able to develop a novel screening system.",{'0': 'we'}
155,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have been ready to develop a novel screening system.",{'0': 'we'}
156,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have chosen to develop a novel screening system.",{'0': 'we'}
157,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have decided to develop a novel screening system.",{'0': 'we'}
158,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have developed a novel screening system.",{'0': 'we'}
159,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we have the ability to develop a novel screening system.",{'0': 'we'}
160,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we may develop a novel screening system.",{'0': 'we'}
161,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we may have developed a novel screening system.",{'0': 'we'}
162,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we might develop a novel screening system.",{'0': 'we'}
163,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we were able to develop a novel screening system.",{'0': 'we'}
164,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we were ready to develop a novel screening system.",{'0': 'we'}
165,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we will develop a novel screening system.",{'0': 'we'}
166,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we will have developed a novel screening system.",{'0': 'we'}
167,EGRAM,"To isolate cDNA clones that dominantly inhibit the DNA-binding activity of Oct-2, chosen as a representative factor, we would develop a novel screening system.",{'0': 'we'}
